Copyright
©2012 Baishideng Publishing Group Co.
World J Gastrointest Pharmacol Ther. Feb 6, 2012; 3(1): 1-6
Published online Feb 6, 2012. doi: 10.4292/wjgpt.v3.i1.1
Published online Feb 6, 2012. doi: 10.4292/wjgpt.v3.i1.1
Table 6 Frequency of adverse events
| Adverse events | LACM7n = 56 (%) | LAC7n = 54 (%) | P value |
| Diarrhea | 17 (30.1) | 13 (24.1) | 0.53 |
| Taste disturbance | 7 (12.5) | 2 (3.7) | 0.16 |
| Loss of appetite | 5 (8.9) | 0 (0.0) | 0.06 |
| Heart burn | 5 (8.9) | 4 (7.4) | 1.00 |
| Nausea | 2 (3.6) | 0 (0.0) | 0.50 |
| Abdominal pain/distention | 7 (12.5) | 3 (5.6) | 0.32 |
| Belching | 3 (5.4) | 2 (3.7) | 1.00 |
| Rash | 0 (0.0) | 1 (1.9) | 0.49 |
| General fatigue | 2 (3.6) | 1 (1.9) | 1.00 |
- Citation: Yanai A, Sakamoto K, Akanuma M, Ogura K, Maeda S. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. World J Gastrointest Pharmacol Ther 2012; 3(1): 1-6
- URL: https://www.wjgnet.com/2150-5349/full/v3/i1/1.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v3.i1.1